Related Experiment Videos
[Atypical antipsychotic drugs]
1Universitair Medisch Centrum, afd. Psychiatrie, Utrecht. r.kahn@psych.azu.nl
Nederlands Tijdschrift Voor Geneeskunde
|September 6, 2000
Summary
New atypical antipsychotics like risperidone, olanzapine, and quetiapine show promise for schizophrenia treatment, reducing negative symptoms and cognitive deficits with fewer side effects than older drugs.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Several new atypical antipsychotics (risperidone, olanzapine, quetiapine) have been introduced.
- These drugs, including earlier clozapine, are characterized by fewer extrapyramidal side effects compared to older antipsychotics.
Purpose of the Study:
- To evaluate the efficacy and side effect profile of new atypical antipsychotics.
- To compare the effectiveness of atypical antipsychotics against traditional antipsychotic medications.
Main Methods:
- Review of recent market introductions of atypical antipsychotics.
- Analysis of existing studies on efficacy and side effect profiles.
Main Results:
- Atypical antipsychotics demonstrate superior efficacy in alleviating negative symptoms and cognitive deficits in schizophrenia.
- These newer agents exhibit a lower incidence of extrapyramidal side effects than older antipsychotics.
Conclusions:
- Atypical antipsychotics represent a significant advancement in schizophrenia management.
- Further head-to-head comparisons and relapse prevention studies are necessary to determine if atypical drugs can fully replace older antipsychotics.